Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.45 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1482143 | 0.99 | EGLN1 (0.58) | EGLN1EGLN3BBOX1ASPHKDM8 | |
| SCHEMBL12828144 | 0.86 | EGLN1 (0.46) | EGLN1 | |
| Hydrochloric Acid SCHEMBL1481993 | 0.85 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL8527848 | 0.84 | EGLN1 (0.44) | EGLN1 | |
| Hydrochloric Acid SCHEMBL1481931 | 0.83 | EGLN1 (0.45) | EGLN1 | |
| SCHEMBL14871022 | 0.81 | EGLN1 (0.46) | EGLN1EGLN3BBOX1ASPHKDM8 | |
| Enarodustat SCHEMBL1481440 | 0.80 | EGLN1 (0.64) | EGLN1EGLN3BBOX1ASPHKDM8 | |
| Enarodustat SCHEMBL21403279 | 0.79 | EGLN1 (0.63) | EGLN1EGLN3BBOX1ASPHKDM8 | |
| Enarodustat SCHEMBL1481939 | 0.79 | EGLN1 (0.65) | EGLN1EGLN3BBOX1ASPHKDM8 | |
| SCHEMBL12828566 | 0.76 | EGLN1 (0.60) | EGLN1EGLN3BBOX1ASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | EGLN1 8/4885EGLN3 1/4885BBOX1 1541/4885 |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | EGLN1 8/4885EGLN3 1/4885BBOX1 1541/4885 |
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | EGLN1 8/4885EGLN3 1/4885BBOX1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.